Education
About Us
Working with TipRanks
Follow Us
uniQure N.V. (QURE)
:QURE
QURE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.73 - $19.18
Previous CloseN/A
Volume1.49M
Average Volume (3M)1.17M
Market Cap
$535.90M
Enterprise Value$996.00M
Total Cash (Recent Filing)-$336.99K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.76
Next Earnings
May 13, 2025Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.92
Shares Outstanding54,076,880
10 Day Avg. Volume1,576,411
30 Day Avg. Volume1,173,628
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)27.32
Price to Cash Flow (P/CF)-3.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit38.53
Enterprise Value/Ebitda-6.20
Forecast
1Y Price Target
$36.29Price Target Upside241.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
uniQure News
See All QURE News
---
Bulls Say, Bears Say
Bulls Say
Product PotentialOur KOLs have been supportive of approval and adoption, indicating confidence in the potential success of AMT-130.
Regulatory ApprovalThe company aligns with the FDA on the components of an accelerated approval BLA for AMT-130 in HD, which could significantly reduce development time.
Bears Say
Financial PerformanceNet loss per share was significantly higher than consensus expectations.
ValuationThe company is perceived as significantly undervalued, suggesting potential upside for investors.
---
Ownership Overview
2.74% Insiders
8.53% Mutual Funds
40.61% Other Institutional Investors
44.03% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $3.73 and its highest was $19.18 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $535.90M.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is May 13, 2025 which is in 40 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Feb 27, 2025. The company reported -$1.49 earnings per share for the quarter, missing the consensus estimate of -$0.653 by -$0.837.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -1.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 54,076,880 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.49 in its last earnings report, missing expectations of -$0.653. Following the earnings report the stock price went up 3.428%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
---
uniQure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.29 (241.71% Upside)
$36.29 (241.71% Upside)
Blogger Sentiment
Bullish
QURE Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 122.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
113.25%
12-Months-Change
Fundamentals
Return on Equity
-238.46%
Trailing 12-Months
Asset Growth
-33.08%
Trailing 12-Months
Company Description
uniQure N.V.
uniQure (QURE) is a biotechnology company specializing in the development of gene therapies. The company is focused on leveraging its gene therapy technology platform to develop treatments for patients with genetic diseases. uniQure's core product offerings are primarily in the field of rare genetic disorders, with a particular emphasis on hemophilia, Huntington's disease, and various cardiovascular and liver-directed gene therapies. The company operates within the pharmaceutical and biotechnology sectors, aiming to deliver transformative therapies that address significant unmet medical needs.
---
QURE Stock 12 Month Forecast
Average Price Target
$36.29
▲(241.71% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Sarepta Therapeutics
―
Bluebird Bio
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Best Analysts Covering QURE
1 Year
1 Year Success Rate
18/39 ratings generated profit
1 Year Average Return
+10.98%
reiterated a buy rating 9 months ago
Copying Debjit Chattopadhyay's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of +10.98% per trade.
---